CompaniesLabPulse.comLatest from LabPulse.comMedical ImagingBiomarker, tissue study shows body composition in patients treated with OzempicBy Liz CareyArtificial intelligence tools may aid healthcare teams in monitoring the negative impacts of weight loss and diabetes drugs.September 20, 2024Diagnostic TechnologiesSolvd Health CEO responds to harsh letter addressing FDA, CMSBy Liz CareySolvd Health CEO Dr. Keri Donaldson responded to critics of his company's machine learning classifier clinical laboratory test that uses genotyping to aid healthcare providers in OUD assessments in adults prior to first-time opioid prescriptions.April 9, 2024Artificial IntelligenceOpentrons Labworks unveils AI-powered workflow toolsBy Matt LimbLab automation and robotics firm Opentrons Labworks Inc has unveiled new tools intended to enhance the efficiency of research across genomics, proteomics, cell biology, and synthetic biology.February 8, 2024Business InsightsHologic receives FDA clearance for digital cytology scanner platform in U.S.By Liz CareyAcknowledging human papillomavirus (HPV) as a causative agent for cervical cancer, the new system is designed to complement molecular testing for HPV with cotesting for cervical cancer.February 2, 2024Policy and RegulationPrecision medicine at tipping point with looming FDA LDT oversightBy Liz CareyFDA targets companion diagnostics (CDx) LDTs first. In addition, CAP and AdvaMedDx set clear expectations, and what to know about the FDA-CMS joint statement on FDA oversight.January 25, 2024Business InsightsTop 10 most read articles in 2023 at LabPulseBy Liz CareyLabPulse.com's top 10 most read articles in 2023 focused on three hot health topics: major cases of fraud and abuse and FDA activities.December 28, 2023Media & PressScience and Medicine Group Launches a Refreshed Platform for LabPulse.com, Moving the Media Property Towards an Increasingly Innovative User ExperienceScience and Medicine Group Launches a Refreshed Platform for LabPulse.com, Moving the Media Property Towards an Increasingly Innovative User ExperienceNovember 15, 2023Heart DiseasePLK1 inhibitors show promise for inflammatory disease treatment, study showsBy Matt LimbA cancer drug in late-stage clinical trials could offer hope for treating a wide range of inflammatory diseases, including gout and heart disease, say researchers.November 14, 2023SequencingGenomics England, Oxford Nanopore to collaborate on sequencing rare diseasesBy Matt LimbGenomics England and Oxford Nanopore Technologies have announced a strategic research partnership to resolve undiagnosed rare disease cases.November 7, 2023COVID-193EO Health to launch FDA-approved COVID-19 testBy Matt LimbMolecular diagnostics startup 3EO Health is preparing to launch a newly approved SARS-CoV-2 test with its portable molecular device, saying it will “expand access” to the technology.October 20, 2023CollaborationOxford Nanopore collaboration makes classroom DNA sequencing accessibleBy Matt LimbAn ambition to make in-classroom DNA sequencing routinely available, more user-friendly, and more egalitarian in U.S. universities and schools has been set out by a leading genetics educator.October 9, 2023BiosensorsPrecision diagnostics finds its “caviar moment”By Matt LimbWhen assembled into networks, the capsules formed the basis of discrete “smart skins” for bodily sensing, capable of recording muscular, breathing, pulse, and blood pressure measurements in real time with ultra-high precision, the academics found.July 10, 2023Laboratory Information Systems (LIS)Epic Systems achieves milestone with exchange of structured genomic data through its EHR systemsBy LabPulse.com staff writersThe landmark moment occurred in April 2023 between two unnamed health organizations when they exchanged clinical information for a patient they cared for in common, using Epic’s Care Everywhere health information exchange functionality.July 5, 2023Business InsightsWeek in Review: Quest to offer ctDNA MRD testing | Exact Sciences develops next-gen Cologuard | Detecting Candida aurisBy Leo O'ConnorQuest Diagnostics completed its previously announced acquisition of Haystack Oncology, a developer of minimal-residual disease (MRD) testing technology.June 22, 2023Business InsightsWeek in Review: Biocartis layoffs | Predicting preeclampsia outcomes | Cystic fibrosis screeningBy Leo O'ConnorRoche announced that its Cobas HPV test has been awarded WHO prequalification, expanding the cervical cancer screening tool's availability in countries that rely on the global organization’s list of prequalified suppliers to purchase tests.June 15, 2023
